BRAF and non-small cell lung carcinoma: Whereas reservations have been very recently raised on the dual inhibition of these targets as a therapeutic opportunity for patients affected by non-small cell lung cancer (NSCLC).101 Although particularly challenging, some possibilities on the identification of innovative B-Raf/EGFR dual inhibitors could also be envisioned on type III allosteric contexts.